July 2026
Our lead CAR T program has received FDA IND clearance for the treatment of patients with gastric and breast cancers
October 2026
We have submitted a pre-IND package for our second CAR T program, currently in development to treat patients with lung, breast, gastric, thyroid, and ovarian cancers.
October 2026
We are actively seeking investors and strategic partners to advance our two lead programs into the clinic, with the goal of delivering new treatment options for patients with no remaining treatment options.
Copyright © 2025 Elatemedical - All Rights Reserved.